13F Holdings
中文EN

PLSH PANACEA LIFE SCIENCES HOLDINGS, INC.

Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1552189 · Fiscal year ends 12/31

Financial factors as of 2023-03-31 (2023Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY-8.7%
TTM net income YoY-3.7%
TTM EPS YoY-14.6%
Revenue 3-yr CAGR19.2%
Net income 3-yr CAGR—

Margins

Gross margin28.4%
Operating margin-288.0%
Net margin-443.5%
FCF margin-137.5%
EBITDA margin-196.4%

Returns

ROE-4,290.8%
ROA-39.8%
ROIC (approx.)-3,336.3%
Asset turnover0.09x

Leverage & solvency

Liabilities / assets120.5%
Debt / equity—
Current ratio0.37x
Interest coverage-2.75x

Cash quality & payout

Operating cash flow / net income0.28x
Accruals ratio-28.7%
Payout ratio—
Capex / revenue13.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20232023-12-31FY20222022-12-31FY20212021-12-31FY20202020-12-31FY20192019-12-31
Income statement
Revenue$2.38M$1.63M$2.06M$9.02M$345,680
Cost of revenue$1.26M$1.23M$1.52M$7.02M$1.94M
Gross profit$1.12M$396,470$540,578$2.00M-$1.70M
R&D expense———$0$22,100
SG&A expense$1.46M$1.09M$1.52M$2.81M$2.82M
Operating income-$5.55M-$5.65M-$5.94M-$5.26M-$10.67M
Interest expense$1.56M$2.05M$1.11M$1.51M$479,111
Pretax income-$8.02M-$9.14M-$4.78M-$5.23M-$10.02M
Net income-$8.02M-$9.14M-$4.78M-$5.23M-$10.02M
EBITDA-$3.83M-$3.98M-$4.26M-$3.63M-$10.61M
EPS (basic)-0.48-0.62-0.28-0.31-0.30
EPS (diluted)-0.48-0.62-0.27-0.31-0.30
Weighted avg. shares (diluted)16.63M14.86M17.82M16.92M33.90M
Balance sheet
Cash & equivalents$100,922$6,951$19,774$84,379$18,405
Short-term investments$14,933$1.11M$3.79M$2.85M—
Receivables$263,970$206,127$244,496$147,302$55,725
Inventory$4.01M$4.45M$4.26M$8.41M$1.34M
Current assets$4.66M$6.38M$9.10M$11.52M$2.43M
PP&E, net$6.45M$7.68M$8.84M$13.59M$477,433
Goodwill$3.01M$2.19M$2.19M$2.19M—
Intangibles$3.01M$2.19M$61,401$122,801$2.15M
Total assets$17.98M$19.49M$23.78M$31.36M$8.02M
Current liabilities$19.45M$15.07M$10.07M$18.26M$3.81M
Short-term debt———$696,286$185,906
Long-term debt———$335,510$185,906
Total debt———$1.03M$371,812
Total liabilities$26.27M$21.63M$16.68M$24.65M$4.13M
Shareholders' equity-$8.29M-$2.14M$7.10M$6.71M$11.94M
Net debt———$947,417$353,407
Shares outstanding17.65M14.97M14.07M16.92M43.82M
Cash flow statement
Operating cash flow-$1.52M-$2.40M-$3.92M-$7.65M-$5.75M
Capital expenditure$65,322$243,804$162,946$3.20M$541,203
Free cash flow-$1.59M-$2.64M-$4.09M-$10.85M-$6.29M
Investing cash flow-$65,322-$196,972$522,533-$3.08M-$2.04M
Financing cash flow$1.68M$2.58M$3.33M$2.30M$7.80M
Depreciation & amortization$1.71M$1.67M$1.68M$1.63M$63,770
Stock-based compensation———$1.35M$3.77M

Free plan shows the latest 5 periods; Pro shows all 10 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.